news
First oral treatment approved for post-transplant refractory cytomegalovirus
The EC has authorised the first UL97 protein kinase inhibitor for adults with post-transplant refractory cytomegalovirus infection.
List view / Grid view
cytomegalovirus (CMV)
news
EMA human medicines committee (CHMP) highlights, September 2022
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.
article
Current innovations in the vaccine pipeline
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
news
NICE recommends Prevymis on the NHS after re-evaluation
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
news
EMA grants marketing authorisation for Prevymis against cytomegalovirus
10 November 2017 | By
The EMA has recommended granting a marketing authorisation Prevymis, an antiviral medicine that prevents CMV reactivation and disease...
news
First-in-human study of CMV vaccine HB-101 starts
20 July 2016 | By Victoria White, Digital Content Producer
Hookipa Biotech has announced the start of a first-in-human study to evaluate the safety and immunogenicity of HB-101 against human cytomegalovirus...
